4. Summary results – evolocumab compared with alternative lipid‐lowering treatments.

Outcome	Number of studies	Intervention		Comparison		Fixed‐effect OR (95% CI)	Fixed‐effect RD (95% CI)
		Events	Available participants	Events	Available participants
Any CVD	1	4	145	3	73	0.66 (0.14 to 3.04)	–0.01 (–0.07 to 0.04)
All‐cause mortality	3	6	3481	7	1742	0.43 (0.14 to 1.30)	–0.00 (–0.01 to 0.01)
Any MI	3	9	3335	8	1668	0.66 (0.23 to 1.85)	–0.00 (–0.00 to  0.00)
Any stroke	2	0	2599	0	1300	NA	NA
Influenza	3	130	3481	53	1742	1.22 (0.88 to 1.70)	0.01 (–0.00 to 0.02)
Type 2 diabetes mellitus	2	3	3336	0	1669	3.52 (0.18 to 68.33)	0.001 (–0.001 to 0.002)
Any cancer	—	—	—	—	—	NA	NA
Hypertension	2	1	3336	0	1669	1.51 (0.06 to 37.04)	0.00 (–0.00 to 0.01)

CI: confidence interval; CVD: cardiovascular disease; MI: myocardial infarction; NA: not available; OR: odds ratio; RD: risk difference.